Content about Mental disorder

May 15, 2013

According to a study published 10 years ago, depression costs $44 billion per year in lost productivity, but a new program is designed to raise awareness about depression in the workforce and its effects on productivity.

CANTON, Ohio — According to a study published 10 years ago, depression costs $44 billion per year in lost productivity, but a new program is designed to raise awareness about depression in the workforce and its effects on productivity.

February 8, 2013

Smoking among adults with mental illnesses is 70% higher than among those without them, according to a new report from the Centers for Disease Control and Prevention.

ATLANTA - Smoking among adults with mental illnesses is 70% higher than among those without them, according to a new report from the Centers for Disease Control and Prevention.

July 30, 2012

In July, the country’s largest trade group representing the drug industry released a report showing nearly 200 drugs under clinical development or Food and Drug Administration review for treating mental disorders.


In July, the country’s largest trade group representing the drug industry released a report showing nearly 200 drugs under clinical development or Food and Drug Administration review for treating mental disorders.


The Pharmaceutical Research and Manufacturers of America released a report listing 187 drugs, including 52 for depression, 37 for schizophrenia and 26 for anxiety disorders.


July 13, 2012

Nearly 200 drugs for mental illnesses are under clinical development or under review by the Food and Drug Administration, the largest lobbying group for the drug industry said Thursday.

WASHINGTON — Nearly 200 drugs for mental illnesses are under clinical development or under review by the Food and Drug Administration, the largest trade group for the drug industry said Thursday.

The Pharmaceutical Research and Manufacturers of America released a report listing 187 drugs, including 52 for depression, 37 for schizophrenia and 26 for anxiety disorders.

April 24, 2012

Mylan has launched a generic drug for treating psychiatric disorders, the company said Tuesday.

PITTSBURGH — Mylan has launched a generic drug for treating psychiatric disorders, the company said Tuesday.

Mylan announced the launch of olanzapine tablets in the 2.5-mg, 5-mg, 7.5-mg, 10-mg, 15-mg and 20-mg strengths.

The drug, a generic version of Eli Lilly's Zyprexa, is used to treat schizophrenia and bipolar disorder. Various versions of the drug had sales of about $3.3 billion in 2011, according to IMS Health.

March 19, 2012

Women take mental health drugs at a much higher rate than men, according to a new study by one of the country's largest pharmacy benefit managers.

WASHINGTON — Women take mental health drugs at a much higher rate than men, according to a new study by one of the country's largest pharmacy benefit managers.

Medco Health Solutions released results of the study Monday, showing that 25% of women use psychotropic drugs, compared with 15% of men. The study was based on the pharmacy claims of more than 2 million Americans and measured the use of drugs for treating depression, anxiety, attention deficit hyperactivity disorder and psychotic disorders between 2001 and 2010.

August 12, 2010

The companies working on more than half of the mental illness drugs under development are...

WASHINGTON The companies working on more than half of the mental illness drugs under development are clustered in four U.S. states, according to research by the largest lobby for the drug industry.

 

The Pharmaceutical Research and Manufacturers of America compiled a study showing that of the 313 drugs, 192 are under development by companies in New York, New Jersey, North Carolina and California. The drugs are in clinical trials or under review by the Food and Drug Administration, PhRMA said.

 

 

July 19, 2010

More than 300 medications for treating mental disorders are in development, according to a new...

WASHINGTON More than 300 medications for treating mental disorders are in development, according to a new report by a pharmaceutical industry lobbying group.